[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2320760A1 - Utilisation therapeutique nouvelle des gangliosides et procede pour leur extraction - Google Patents

Utilisation therapeutique nouvelle des gangliosides et procede pour leur extraction

Info

Publication number
FR2320760A1
FR2320760A1 FR7540170A FR7540170A FR2320760A1 FR 2320760 A1 FR2320760 A1 FR 2320760A1 FR 7540170 A FR7540170 A FR 7540170A FR 7540170 A FR7540170 A FR 7540170A FR 2320760 A1 FR2320760 A1 FR 2320760A1
Authority
FR
France
Prior art keywords
paralysis
nervous
tetra
tri
conduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7540170A
Other languages
English (en)
French (fr)
Other versions
FR2320760B1 (it
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia SpA filed Critical Fidia SpA
Publication of FR2320760A1 publication Critical patent/FR2320760A1/fr
Application granted granted Critical
Publication of FR2320760B1 publication Critical patent/FR2320760B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR7540170A 1975-08-13 1975-12-30 Utilisation therapeutique nouvelle des gangliosides et procede pour leur extraction Granted FR2320760A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT26323/75A IT1046051B (it) 1975-08-13 1975-08-13 Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione

Publications (2)

Publication Number Publication Date
FR2320760A1 true FR2320760A1 (fr) 1977-03-11
FR2320760B1 FR2320760B1 (it) 1978-11-17

Family

ID=11219226

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7540170A Granted FR2320760A1 (fr) 1975-08-13 1975-12-30 Utilisation therapeutique nouvelle des gangliosides et procede pour leur extraction

Country Status (7)

Country Link
JP (2) JPS5234912A (it)
AT (1) AT352296B (it)
BE (1) BE843695A (it)
DE (1) DE2549680A1 (it)
ES (1) ES441233A1 (it)
FR (1) FR2320760A1 (it)
IT (1) IT1046051B (it)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001875A1 (fr) * 1979-03-16 1980-09-18 Merieux Inst Nouveau medicament, notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant
FR2451194A1 (fr) * 1979-03-16 1980-10-10 Merieux Inst Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant
EP0038511A2 (en) * 1980-04-17 1981-10-28 Rolf Dr. Schäfer Wound healing compositions
WO1981003175A1 (en) * 1980-05-09 1981-11-12 H Leffler Carbohydrate derivatives for inhibiting bacterial adherence
EP0126817A1 (en) * 1983-05-27 1984-12-05 Shanksville Corporation N.V. Suppressing of graft rejection in organ transplantation
EP0332191A2 (en) * 1988-03-10 1989-09-13 Mect Corporation Sialosyl glyceride and process for producing the same
EP0409473A2 (en) * 1989-07-12 1991-01-23 Beta S.A. Laboratorios A process for obtaining the gangliosides from nervous tissue of mammalians and for the treatment of psychoorganic diseases with said material compositons

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222424A (ja) * 1983-06-01 1984-12-14 Katsutaka Nagai 神経障害疾患治療剤
IT1177863B (it) * 1984-07-03 1987-08-26 Fidia Farmaceutici Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1232176B (it) 1989-07-27 1992-01-25 Fidia Farmaceutici Derivati di-lisogangliosidi
IT1238346B (it) * 1989-11-14 1993-07-13 Gangliosidi modificati e loro derivati funzionali.
JPH0580009A (ja) * 1991-09-20 1993-03-30 Kubota Corp 炭酸濃度測定方法
JPH0580010A (ja) * 1991-09-25 1993-03-30 Kubota Corp 気体中の炭酸ガス濃度測定方法
JP4005115B1 (ja) * 2007-02-08 2007-11-07 日本臓器製薬株式会社 疼痛疾患治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT127981B (de) * 1929-06-07 1932-04-25 Schering Kahlbaum Ag Verfahren zur Herstellung eines die zentralen Tätigkeiten fördernden und regulierenden Reizstoffes.
CH193176A (de) * 1936-12-08 1937-09-30 Richter Arthur Verfahren zur Gewinnung eines Wirkstoffes aus Säugetiergehirn.
US3436413A (en) * 1965-12-21 1969-04-01 Canada Packers Ltd Process for the isolation of phosphatidyl serine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, VOL.57, REF. 12858H 1962 ) *
CHEMICAL ABSTRACTS, VOL.78, REF. 81662C 1973 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001875A1 (fr) * 1979-03-16 1980-09-18 Merieux Inst Nouveau medicament, notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant
EP0016702A1 (fr) * 1979-03-16 1980-10-01 Institut Merieux Médicament, notamment pour le traitement du choléra, et compositions pharmaceutiques le contenant
FR2451194A1 (fr) * 1979-03-16 1980-10-10 Merieux Inst Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant
EP0038511A2 (en) * 1980-04-17 1981-10-28 Rolf Dr. Schäfer Wound healing compositions
EP0038511A3 (en) * 1980-04-17 1982-08-18 Rolf Dr. Schaefer Wound healing compositions
WO1981003175A1 (en) * 1980-05-09 1981-11-12 H Leffler Carbohydrate derivatives for inhibiting bacterial adherence
US4464360A (en) * 1980-05-09 1984-08-07 Hakon Leffler Glycosphingalipids for inhibiting bacterial adherence
EP0126817A1 (en) * 1983-05-27 1984-12-05 Shanksville Corporation N.V. Suppressing of graft rejection in organ transplantation
EP0332191A2 (en) * 1988-03-10 1989-09-13 Mect Corporation Sialosyl glyceride and process for producing the same
EP0332191A3 (en) * 1988-03-10 1990-05-16 Mect Corporation Sialosyl glyceride and process for producing the same
EP0409473A2 (en) * 1989-07-12 1991-01-23 Beta S.A. Laboratorios A process for obtaining the gangliosides from nervous tissue of mammalians and for the treatment of psychoorganic diseases with said material compositons
EP0409473A3 (en) * 1989-07-12 1992-04-29 Carlos Mammarella A process for obtaining the gangliosides from nervous tissue of mammalians and for the treatment of psychoorganic diseases with said material compositons

Also Published As

Publication number Publication date
DE2549680A1 (de) 1977-02-24
DE2549680C2 (it) 1988-05-11
FR2320760B1 (it) 1978-11-17
JPS5234912A (en) 1977-03-17
JPS62187412A (ja) 1987-08-15
IT1046051B (it) 1980-06-30
ES441233A1 (es) 1977-03-16
JPS6256134B2 (it) 1987-11-24
AT352296B (de) 1979-09-10
BE843695A (fr) 1976-11-03
JPS6250450B2 (it) 1987-10-24
ATA606976A (de) 1979-02-15

Similar Documents

Publication Publication Date Title
FR2320760A1 (fr) Utilisation therapeutique nouvelle des gangliosides et procede pour leur extraction
PT77471A (en) Devices for administering medicaments to patients
ATE350041T1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
AU8375682A (en) Nonapeptide for treatment of drug withdrawal symptoms
DE3176800D1 (en) Oligosaccharides having selective anticoagulation activity
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE3263327D1 (en) Immune adsorbent, adsorbing device and blood purifying apparatus
ES526990A0 (es) Un procedimiento para preparar un adsorbido de medicamento
MY103741A (en) Process for producing an administration and/or dosage form for medicinal active substances by means of a printing process
KR950016715A (ko) 당의형 약학적 투여 단위
JPS5246060A (en) Delta 155steroid * preparation thereof and pharmaceutical agent containing the same
PT79466A (en) A kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor
ZA81706B (en) Device for the administration of medicaments
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
JPS52108028A (en) Remedies for dysacousis
Gonzales Postherpes simplex type 1 neuralgia simulating postherpetic neuralgia
JPS55113721A (en) Immunity regulator
JPS5230090A (en) Device for intaking to remove contrast liquid from patient*s spinal canal
EP0109859A3 (en) Process for purifying and separating vatimin b12
JPS51120417A (en) Systems for distributing liquid and recovery of vapor
US4725625A (en) Pharmaceutical composition and method for treating cachexia in humans due to cancer
JPS5639019A (en) Antiviral agent
MCQUILLEN Hazard from antibiotics in myasthenia gravis
Greydanus et al. Akute Enzephalopathie mit Leberdysfunktion, chylösem Aszites und Zytomegalie-Virusinfektion
SU1466754A1 (ru) Способ лечени рассе нного склероза